Page 118 - PCC10

Take-Home Message
• CD133+ are EPCs that represent an Advanced Therapy Medicinal Product (ATMP)
• CD133+ has been considered to be ODD by the EMA based on prevalence,
biological plausibility and significant benefit in Asherman’s Syndrome
• The benefits of CD133+ cells seem to be mostly based on Neoangiogenesis and Tissue Remodelling and Regeneration
• Further clinical and PC studies are required to establish, dosage, potency and determine more precisely MoA of this therapy
Acknowledgements
 IVI Valencia
• Dr Sergio Cabanillas • Dr. Jaime Ferro
• Prof. Jose Remohí
• Prof. Antonio Pellicer
 Hospital Clínico Universitario de Valencia • Haematology Department
• Dra. Cristina Arbona • Radiology Department
• Dr. Julio Palmero
• Ob/Gyn Department
• Dr. Francisco Raga
 Fundación IVI
• Irene Cervelló
• Claudia Gil-Sanchis • Amparo Faus
• A.Diaz
 Igenomix
• Prof. Carlos Simón
• Dra. Diana Valbuena • Carlos Gómez Cruz
Page 112 of 135
118